Allogene Therapeutics (ALLO) Ownership - Who Owns Allogene Therapeutics?

1,768 Followers

Allogene Therapeutics (ALLO) Ownership Overview

6.67% Insiders

7.95% Mutual Funds

23.39% Other Institutional Investors

7.85% ETFs

54.13% Public Companies and

Individual Investors

The ownership structure of Allogene Therapeutics (ALLO) stock is a mix of institutional, retail, and individual investors. Approximately 39.19% of the company’s stock is owned by Institutional Investors, 6.67% is owned by Insiders, and 54.13% is owned by Public Companies and Individual Investors.

The ownership structure of Allogene Therapeutics (ALLO) stock is a mix of institutional, retail, and individual investors. Approximately 31.34% of the company’s stock is owned by Institutional Investors, 6.67% is owned by Insiders, and 7.85% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date	Name	Activity	Value

Show More Insider Trading Activity >

Recent Hedge Fund Trading Activity

Date	Firm	Activity	Value
Mar 31, 2024	Graham Capital Management, L.p.	xxxxxxxxxxxxx	$105564
Mar 31, 2024	Primecap Management Co	xxxxxxxxxxxxx	$20446810
Mar 31, 2024	Woodline Partners Lp	xxxxxxxxxxxxx	$8542630

Show More Hedge Fund Trading Activity >

Top Shareholders

Holder	# of Shares	Type	% Holding	Value
	11,009,103	Insider	3.19%	22,018,206
	8,631,176	Institution	2.50%	17,262,352
Theofanis Kolokotrones	8,379,840	Institution	2.43%	16,759,680
	8,063,795	Insider	2.34%	16,127,590
	7,379,427	Institution	2.14%	14,758,854
	6,678,789	Institution	1.94%	13,357,578
	6,167,257	Institution	1.79%	12,334,514
	5,189,570	Institution	1.50%	10,379,140
Michael Rockefeller	3,501,078	Institution	1.01%	7,002,156
Len Potter	2,920,787	Institution	0.85%	5,841,574

Top Mutual Fund Holders

# of Shares	Type	% Holding	Value
6,678,789	Institution	1.94%	13,357,578
5,189,570	Institution	1.50%	10,379,140
2,745,270	Institution	0.80%	5,490,540
2,147,980	Institution	0.62%	4,295,960
1,733,105	Institution	0.50%	3,466,210
1,709,989	Institution	0.50%	3,419,978
1,401,115	Institution	0.41%	2,802,230
1,208,862	Institution	0.35%	2,417,724
885,754	Institution	0.26%	1,771,508
600,290	Institution	0.17%	1,200,580

Top ETF Holders

Holder	# of Shares	Type	% Holding	Value
SPDR S&P BIOTECH ETF	5,886,674	Institution	1.71%	13,421,617
Vanguard Total Stock Market ETF	4,879,191	Institution	1.41%	11,905,226
iShares Russell 2000 ETF	3,644,583	Institution	1.06%	8,382,541
Vanguard Extended Market ETF	1,883,094	Institution	0.55%	4,594,749
iShares Biotechnology ETF	1,676,161	Institution	0.49%	3,855,170
iShares Russell 2000 Value ETF	1,348,351	Institution	0.39%	3,101,207
Schwab U.S. Small-Cap ETF	1,226,517	Institution	0.36%	2,796,459
Dimensional U.S. Small Cap ETF	885,927	Institution	0.26%	2,019,914
Fidelity Enhanced Small Cap ETF	834,845	Institution	0.24%	1,903,447
Vanguard Russell 2000 ETF	769,244	Institution	0.22%	1,876,955

FAQ

Who Owns Allogene Therapeutics (ALLO)?

According to the latest TipRanks data, approximately 23.39% of the company's stock is held by institutional investors, 6.67% is held by insiders, and 54.13% is held by retail investors.

What percentage of Allogene Therapeutics (ALLO) stock is held by institutional investors?

According to the latest TipRanks data, approximately 23.39% of Allogene Therapeutics (ALLO) stock is held by institutional investors.

What percentage of Allogene Therapeutics (ALLO) stock is held by retail investors?

According to the latest TipRanks data, approximately 54.13% of Allogene Therapeutics (ALLO) stock is held by retail investors.

Who owns the most shares of Allogene Therapeutics (ALLO)?

Arie Belldegrun owns the most shares of Allogene Therapeutics (ALLO).

What is the significance of the ownership structure for a publicly traded company?

The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.